|Bid||4.5400 x 1200|
|Ask||4.5700 x 21500|
|Day's Range||4.5500 - 4.9400|
|52 Week Range||1.7600 - 6.1300|
|Beta (5Y Monthly)||2.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 05, 2020 - Feb 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.50|
ImmunoGen Announces Webcast of Presentation and Q&A at the 38th Annual J.P. Morgan Healthcare Conference
FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine.
These four stocks are moving on news and gaining technical momentum. Axsome Therapeutics (AXSM) jumped $8.60 to $89.57 on 2.6 million shares Wednesday, more than double its average volume. On Monday the biotech company said its experimental treatment for depression met the primary endpoint in a Phase 3 clinical trial.
These four stocks are moving on news and gaining technical momentum: Axsome Therapeutics, Inc . (NASDAQ: AXSM ) jumped $8.60 to $89.57 on 2.6 million shares Wednesday, more than double its average volume. ...
FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine. Shares up.
Shares of ImmunoGen Inc. gained 18% in afternoon trading after the biotechnology company announced that the Food and Drug Administration had cleared a trial for its investigational ovarian cancer drug to be used to support accelerated approval. The drug, mirvetuximab soravtansine, is being tested as a treatment for some women with ovarian cancer who have previously been treated with Avastin, a Roche cancer therapy. The company aims to submit the therapy to the regulator in the second half of 2021. ImmunoGen's stock is down 4.11% year-to-date. The S&P 500 has gained about 27%.
ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Piper Jaffray Healthcare Conference. The fireside chat is scheduled for 12:30 p.m. ET on December 3, 2019. A webcast of the fireside chat will be accessible live through the “Investors & Media” section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.
Roche's (RHHBY) breast cancer candidate and lymphona candidate get positive CHMP opinion. The company inks a deal to acquire Promedior, Inc.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
Updated Phase 1 Data to be Highlighted in Oral Presentation Demonstrate Tolerable Safety Profile and Encouraging Activity in AML and BPDCN
A look at the shareholders of ImmunoGen, Inc. (NASDAQ:IMGN) can tell us which group is most powerful. Insiders often...
ImmunoGen (IMGN) reports narrower-than-expected third-quarter loss and beats revenue estimates. The company is set to initiate the FDA recommended phase III study on mirvetuximab soravtansine by year-end.
ImmunoGen (IMGN) delivered earnings and revenue surprises of 21.05% and 45.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 1, 2019 to discuss its third quarter operating results. ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days.